Patents by Inventor Susanne Kammler

Susanne Kammler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOB Antisense Conjugate Compounds
    Publication number: 20160289677
    Abstract: The present invention relates to conjugates of antisense oligonucleotides (oligomers) that target the APOB gene at position 2265 to 2277.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 6, 2016
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Marie Lindholm, Mark Turner, Henrik Orum
  • LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
    Publication number: 20150368642
    Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 24, 2015
    Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW
  • ANTI APOB ANTISENSE CONJUGATE COMPOUNDS
    Publication number: 20150291958
    Abstract: The present invention relates to conjugates of LNA antisense oligonucleotides (oligomers) that target ApoB.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 15, 2015
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albaek, Henrik Frydenlund Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum, Mark Turner, Marie Lindholm
  • Oligonucleotide Conjugates
    Publication number: 20150275212
    Abstract: The invention relates to the field of oligonucleotide therapeutics, and in particular to the use of a cleavable, e.g. a phosphodiester region covalently attached to a conjugate, a targeting group or blocking group to enhance the properties of the oligonucleotides, for example to improve the therapeutic index.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 1, 2015
    Inventors: Nanna Albaek, Henrik Hansen, Susanne Kammler, Jacob Ravn, Henrik Orum
  • COMPOUNDS FOR THE MODULATION OF SMN2 SPLICING
    Publication number: 20140343127
    Abstract: The present invention relates to oligomer compounds (oligomers) which target nucleic acids encoding human SMN2 in a cell, leading to modulation of SMN2 mRNA splicing which favors full length SMN2 mRNA rather than the poorly functional truncated transcript, SMN2 ?7. Reduction of SMNA7 mRNA expression and/or increase in full length SMN2 mRNA expression are beneficial for the treatment of diseases or disorders associated with overexpression or undesirably high levels of aberrant forms of SMN2, particularly SMN2 ?7, such as spinal muscular atrophy (SMA).
    Type: Application
    Filed: November 8, 2012
    Publication date: November 20, 2014
    Inventor: Susanne Kammler